C. Ola Landgren, Leader of Translational & Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“Moving cancer care forward requires a continuous exchange between discovery and patient care, from the laboratory to the clinic, from the clinic back to the laboratory, and back to patients with better answers.
That spirit brought us together yesterday in Miami at Sylvester Comprehensive Cancer Center, University of Miami, for our inter-programmatic research retreat, jointly hosted by Translational & Clinical Oncology, which I co-lead with Dr. Jaime Merchan, and Tumor Biology, led by Dr. Priyamvada Rai and Dr. Scott Welford.
Three presentations highlighted the power of bringing scientific and clinical expertise together:
- Metabolism-modifying interventions in high-risk prostate cancer: Dr. Priyamvada Rai and Dr. Marijo Bilusic.
- Discovery and development of a novel technology to prevent chemotherapy side effects: Dr. Xiang-Xi Mike Xu and Dr. Tongyu Cao Wikramanayake.
- Overcoming therapeutic resistance via dual-targeted and DNA-damaging synergies: Dr. Justin Taylor and Dr. Austin Dosch.
Each reflects why translational research is critically important: understanding cancer biology helps us develop better treatments, while learning from patients helps us ask more meaningful scientific questions. Through this continuous exchange, we seek to overcome treatment resistance, improve outcomes and quality of life, and ultimately develop curative treatments.
I am especially grateful to the patients who participate in our studies. Their trust and contributions make progress possible and help shape care for future patients.
I am equally grateful to our nurses, APRNs, doctors, pharmacists, scientists, postdocs, and all support staff. Every discovery and every clinical study depends on people bringing their expertise together around a shared purpose.
Together, we are building a culture of team science, grounded in excellence, innovation, and collaboration. Our shared ambition is to translate discoveries into lasting benefits for patients and bring the possibility of cure within reach for more people with cancer.”
Other articles featuring C. Ola Landgren on OncoDaily.